Navigation Links
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.

The poster presentation entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," is scheduled to be presented on June 2, 2008.

About ANX-510, or CoFactor

CoFactor is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-fluorouracil). Compared to leucovorin, CoFactor creates more stable binding between the active form of 5-FU and the target enzyme, thymidylate synthase. CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, potentially allowing 5-FU to work more effectively.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the potential for ADVENTRX's product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; difficulties or delays in developing, testing, manufacturing and marketing of and obtaining regulatory approval for ADVENTRX's product candidates; the market potential for ADVENTRX's product candidates and ADVENTRX's and any future partners' ability to compete in those markets; unexpected adverse side effects or inadequate therapeutic efficacy of ADVENTRX's product candidates that could delay or prevent regulatory approval or commercialization; the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or as otherwise anticipated; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Genzyme Announces Presentation of New Positive Data on Carticel(R)
7. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... Cell Therapy Catapult to advance development of large ... cell immunotherapy. Under the agreement, the Cell Therapy ... AST-VAC2 to support advanced clinical trials and eventual ... --> The Cell Therapy Catapult is ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... An increasing number ... Association (FAA) has partnered with the Florida Department of Health and its Bureau ... The FAA Smoke-Free Multifamily Housing Program launched last week at the organization’s 2015 ...
(Date:10/13/2015)... ... 13, 2015 , ... Bambeco, Inc., the premier brand for ... it closed on a $20.5 million funding round led by ABS Capital Partners, ... Company’s continued rapid growth and expansion, broaden the Company’s product offerings, and expand ...
(Date:10/13/2015)... Los Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... game. To incentivize would-be customers, eMarketing Concepts began a $1 promotion – effectively offering ... was a resounding success, and within weeks the company was flooded with phone calls ...
(Date:10/13/2015)... ... October 13, 2015 , ... SPH Analytics today announced the ... organization’s Executive Vice President of Operations, and three Senior Vice Presidents, Robert Davis, ... the company. , Debbie Vereb’s appointment to Executive Vice President of Operations at ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... a new PDF automation tool to batch conversions of CAD drawings, plans, ... 100% document fidelity. , CADConverter eliminates the complexity requirement of specialized applications to ...
Breaking Medicine News(10 mins):